Why Providers Can’t Ignore CMS Audits

At the end of the day, it doesn’t matter what your patient mix looks like; your notes can and will be pulled into audits. Waiting until CMS is at your doorstep isn’t a strategy — it’s a risk. Now is the moment to get ahead of it. The post Why Providers Can’t Ignore CMS Audits…

Read More

Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer’s Drug

Korsana Biosciences’ preclinical Alzheimer’s disease drug comes from a platform technology that enables antibodies to cross the blood-brain barrier. Roche and AbbVie have clinical-stage drugs taking a similar approach to Alzheimer’s. The post Startup Korsana Bio Reveals $175M Raised for a Better Brain-Penetrating Alzheimer’s Drug appeared first on MedCity News.

Read More